Evolution is a brilliant but slow designer. Vilya is betting that artificial intelligence can do it better, faster, and in ways nature never intended. They aren't just discovering drugs; they are inventing macrocyclic therapeutics from the ground up, targeting the 'undruggable' with a precision that biology alone cannot achieve.

"They aren't just discovering drugs; they are inventing macrocycles evolution never imagined."

The biotech landscape is crowded with AI drug discovery startups, but Vilya differentiates by focusing specifically on macrocycles—large, ring-shaped molecules that can bind to protein surfaces with high specificity. Traditional small molecules often fail here, and biologics are too large. Vilya sits in the 'Goldilocks zone,' using AI to navigate the vast chemical space of macrocycles that are too complex for human intuition.

• Tech Stack: Built on Svelte and Astro, indicating a modern, performance-obsessed engineering culture.
• Market Position: Targets the 'undruggable' proteome with synthetic biology.
• Funding Runway: $73.8M in the bank suggests a long runway for R&D without immediate pressure for dilutive rounds.